Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  La Monica, Silvia ^a   Caffarra, Cristina ^a   Saccani, Francesca ^a   Galvani, Elena ^a,b   Galetti, Maricla ^a   Fumarola, Claudia ^a   Bonelli, Mara ^a   Cavazzoni, Andrea ^a   Cretella, Daniele ^a   Sirangelo, Rita ^a   Gatti, Rita ^a   Tiseo, Marcello ^c   Ardizzoni, Andrea ^c   Giovannetti, Elisa ^b   Petronini, Pier Giorgio ^a   Alfieri, Roberta R ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NERVE CELL ADHESION MOLECULE; PROTEIN TYROSINE KINASE; STAT5 PROTEIN; SYNAPTOPHYSIN; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MET PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EXPOSURE; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOLECULAR MECHANICS; ONCOGENE; ONCOGENE MET; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; UPREGULATION; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84885985813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078656     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi:10.3322/caac.20138. PubMed: 22237781.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. doi:10.1056/NEJMoa040938. PubMed: 15118073.
3. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. doi:10.1126/science.1099314. PubMed: 15118125.
4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311. doi:10.1073/pnas.0405220101. PubMed: 15329413.
5. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227. doi:10.1016/j.ccr.2006.12.017. PubMed: 17349580.
6. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, et al. (2006) Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66: 8163-8171. doi:10.1158/0008-5472.CAN-06-0453. PubMed: 16912195.
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957. doi:10.1056/NEJMoa0810699. PubMed: 19692680.
8. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128. doi:10.1016/S1470-2045(09)70364-X. PubMed: 20022809.
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246. doi:10.1016/S1470-2045(12)70228-0. PubMed: 22285168.
10. Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, et al. (2013) Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Curr Pharm Des 19: 818-832. doi:10.2174/138161213804547222. PubMed: 22973953.
11. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792. doi:10.1056/NEJMoa044238. PubMed: 15728811.
12. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS Med 2: e73. doi:10.1371/journal.pmed.0020073. PubMed: 15737014.
13. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. doi:10.1126/science.1141478. PubMed: 17463250.
14. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932-20937. doi:10.1073/pnas.0710370104. PubMed: 18093943.
15. Yu H, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, et al. (2013) Analysis of Mechanisms of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR-mutant Lung Cancers. Clin Cancer Res.
16. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26. PubMed: 21430269.
17. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD, (2008) Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 25: 843-854. doi:10.1007/s10585-008-9200-4. PubMed: 18696232.
18. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, et al. (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698. doi:10.1158/1078-0432.CCR-05-1492. PubMed: 16361555.
19. Asami K, Okuma T, Hirashima T, Kawahara M, Atagi S, et al. (2013) Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations. Lung Cancer 79: 276-282. doi:10.1016/j.lungcan.2012.11.022. PubMed: 23261231.
20. Faehling M, Eckert R, Kamp T, Kuom S, Griese U, et al. (2013) EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival. Lung Cancer 80: 306-312. doi:10.1016/j.lungcan.2013.02.010. PubMed: 23489557.
21. Nishie K, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, et al. (2012) Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 7: 1722-1727. doi:10.1097/JTO.0b013e31826913f7. PubMed: 23059777.
22. Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, et al. (2013) Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 79: 283-288. doi:10.1016/j.lungcan.2012.11.007. PubMed: 23254265.
23. Watanabe S, Tanaka J, Ota T, Kondo R, Tanaka H, et al. (2011) Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer 11: 1. doi:10.1186/1471-2407-11-1. PubMed: 21194487.
24. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, et al. (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13: 5150-5155. doi:10.1158/1078-0432.CCR-07-0560. PubMed: 17785570.
25. Hata A, Katakami N, Kaji R, Fujita S, Imai Y, (2013) Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol 8: e27-e29. doi:10.1097/JTO.0b013e318282e047. PubMed: 23407566.
26. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, et al. (2011) Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 17: 6298-6303. doi:10.1158/1078-0432.CCR-11-1468. PubMed: 21856766.
27. La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, et al. (2009) Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 78: 460-468. doi:10.1016/j.bcp.2009.04.033. PubMed: 19427302.
28. Cavazzoni A, Alfieri RR, Carmi C, Zuliani V, Galetti M, et al. (2008) Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol Cancer Ther 7: 361-370. doi:10.4161/cbt.7.3.5582. PubMed: 18281519.
29. Fumarola C, La Monica S, Alfieri RR, Borra E, Guidotti GG, (2005) Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ 12: 1344-1357. doi:10.1038/sj.cdd.4401660. PubMed: 15905878.
30. Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, et al. (2010) Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci 101: 167-172. doi:10.1111/j.1349-7006.2009.01368.x. PubMed: 19804422.
31. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, et al. (2011) Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3: 90ra59. PubMed: 21734175.
32. Galvani E, Giovannetti E, Saccani F, Cavazzoni A, Leon LG, et al. (2013) Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. Neoplasia 15: 61-72. PubMed: 23359111.
33. Larue L, Bellacosa A, (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 24: 7443-7454. doi:10.1038/sj.onc.1209091. PubMed: 16288291.
34. Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS, et al. (2012) Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene (. (2013)) PubMed: 23160379.
35. Maitah MY, Ali S, Ahmad A, Gadgeel S, Sarkar FH, (2011) Up-regulation of sonic hedgehog contributes to TGF-beta1-induced epithelial to mesenchymal transition in NSCLC cells. PLOS ONE 6: e16068. doi:10.1371/journal.pone.0016068. PubMed: 21249152.
36. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, et al. (2011) Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6: 1152-1161. doi:10.1097/JTO.0b013e318216ee52. PubMed: 21597390.
37. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, et al. (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944-950. doi:10.1158/0008-5472.CAN-05-1988. PubMed: 16424029.
38. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, et al. (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275: 8806-8811. doi:10.1074/jbc.275.12.8806. PubMed: 10722725.
39. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, et al. (2002) Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 8: 2273-2285. PubMed: 12114431.
40. Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105: 692-697. doi:10.1073/pnas.0707270105. PubMed: 18180459.
41. Guarino M, (2010) Src signaling in cancer invasion. J Cell Physiol 223: 14-26. PubMed: 20049846.
42. Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, et al. (2010) Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer 17: 481-493. doi:10.1677/ERC-09-0328. PubMed: 20233708.
43. Quesnelle KM, Boehm AL, Grandis JR, (2007) STAT-mediated EGFR signaling in cancer. J Cell Biochem 102: 311-319. doi:10.1002/jcb.21475. PubMed: 17661350.
44. Das S, Roth CP, Wasson LM, Vishwanatha JK, (2007) Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 67: 1550-1564. doi:10.1002/pros.20640. PubMed: 17705178.
45. Merk BC, Owens JL, Lopes MB, Silva CM, Hussaini IM, (2011) STAT6 expression in glioblastoma promotes invasive growth. BMC Cancer 11: 184. doi:10.1186/1471-2407-11-184. PubMed: 21595984.
46. Cuenda A, Rousseau S, (2007) p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358-1375. doi:10.1016/j.bbamcr.2007.03.010. PubMed: 17481747.
47. Kwon CH, Moon HJ, Park HJ, Choi JH, Park do Y, (2013) S100A8 and S100A9 promotes invasion and migration through p38 mitogen-activated protein kinase-dependent NF-kappaB activation in gastric cancer cells. Mol Cells 35: 226-234. doi:10.1007/s10059-013-2269-x. PubMed: 23456298.
48. Wang XF, Zhou QM, Du J, Zhang H, Lu YY, et al. (2013) Baicalin Suppresses Migration, Invasion and Metastasis of Breast Cancer via p38MAPK Signaling Pathway. Anti Cancer Agents Med Chem 13: 923-931. doi:10.2174/18715206113139990143. PubMed: 23387975.
49. Nurwidya F, Takahashi F, Murakami A, Takahashi K, (2012) Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 44: 151-156. doi:10.4143/crt.2012.44.3.151. PubMed: 23091440.
50. Palacios F, Tushir JS, Fujita Y, D'Souza-Schorey C, (2005) Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Cell Biol 25: 389-402. doi:10.1128/MCB.25.1.389-402.2005. PubMed: 15601859.